Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab in combination with standard of care treatments for multiple myeloma was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2021-04-08